You are here

  • Home
  • Archive
  • Volume 78, Issue Suppl 2
  • FRI0379 LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL

Article metrics

Article menu

Download PDFPDF

Spondyloarthritis – treatment
FRI0379 LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
Free

 

Online download statistics by month:

Online download statistics by month: May 2019 to March 2024

AbstractFullPdf
May 2019601
Jun 201934034
Jul 2019117031
Aug 2019108017
Sep 201965013
Oct 201983048
Nov 201967016
Dec 2019100021
Jan 202068026
Feb 20204804
Mar 2020135031
Apr 202060010
May 202090011
Jun 2020138022
Jul 202067012
Aug 20204507
Sep 20204907
Oct 202058016
Nov 20203204
Dec 20201701
Jan 20211705
Feb 20212608
Mar 20213506
Apr 20213806
May 20211107
Jun 2021006
Jul 2021005
Aug 20211011
Sep 2021007
Oct 202122022
Nov 202136018
Dec 20215006
Jan 20221402
Feb 20221201
Mar 20222005
Apr 20224205
May 202240011
Jun 20221404
Jul 202278025
Aug 20224309
Sep 20222406
Oct 20221503
Nov 20221205
Dec 2022802
Jan 20232004
Feb 20231609
Mar 20232704
Apr 20231202
May 2023603
Jun 20231004
Jul 20232609
Aug 2023403
Sep 20231001
Oct 202336010
Nov 20231005
Dec 20232001
Jan 2024403
Feb 20241000
Mar 202410015
Total21660590